GeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development Platform

DURHAM, NC, May 30, 2017— GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.  In his role as CBO, Mr. Capone will lead the expansion in pharmaceutical and biotechnology company drug development collaborations involving GeneCentric’s Cancer Subtyping Platform (CSP™), and will oversee the company’s commercial strategy and growth.  As a Director, Ms. Lubman will augment GeneCentric’s industry and partnership development focus.